A5076707867- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Gastrointestinal Tumor Research and Treatment
- Plant Diversity and Evolution
- Plant and animal studies
- Ecology and Vegetation Dynamics Studies
- Pancreatic and Hepatic Oncology Research
- Neuroblastoma Research and Treatments
- Esophageal and GI Pathology
- Colorectal and Anal Carcinomas
- Viral-associated cancers and disorders
- Salivary Gland Tumors Diagnosis and Treatment
- Cervical Cancer and HPV Research
- Liver Disease and Transplantation
- Pituitary Gland Disorders and Treatments
- Gallbladder and Bile Duct Disorders
- Multiple and Secondary Primary Cancers
Hospices Civils de Lyon
2019-2023
Hôpital de la Croix-Rousse
2023
Hôpital Edouard Herriot
2016-2020
HCL Technologies (India)
2019
Hôpital Beaujon
2017
University of Edinburgh
2016
Small rectal neuroendocrine tumours are good candidates for endoscopic resection provided that complete pathological (R0) is obtained and their risk of metastatic progression low. We conducted a large multicentre nationwide study to evaluate the outcomes management non-metastatic ≤2 cm diagnosed endoscopically.The medical records, findings patients with managed from January 2000-June 2018 in 16 French hospitals, were retrospectively analysed. The primary objective was describe proportion R0...
When initial resection of rectal neuroendocrine tumors (r-NETs) is not R0, persistence local residue could lead to disease recurrence. This study aimed evaluate the interest systematic non-R0 r-NET scars.
First-line chemotherapy in metastatic neuroendocrine carcinomas (NECs) is based on etoposide and platinum. However, there no standard concerning second-line treatment. The objective of this study was to evaluate efficacy tolerance dacarbazine or temozolomide digestive NEC as post first-line treatment.This included patients with a unknown primary site. All received platinum-etoposide chemotherapy. Primary endpoint progression-free survival (PFS). Secondary endpoints were...
Most rectal neuroendocrine tumors (rNETs) are small (≤ 20 mm) and incidentally discovered at a localized stage during endoscopic procedures for unrelated indications [1]. Endoscopically, rNET, as presented here in first example, is usually unique yellowish submucosal nodule, embedded the wall, with round shape pit pattern, type I on Kudo classification, invisible vessels, described by Sano ([Fig. 1 – c]). Histologic analysis of such lesions shows them to be grade World Health Organization...
Hepaticogastrostomy is an alternative to biliary drainage after endoscopic retrograde cholangiopancreatography (ERCP) failure [1] [2]. However, this technique associated with higher morbidity, including stent migration [3] and bleeding [4]. Bleeds are mostly due pseudoaneurysm of the hepatic arteries [5].
Un traitement endoscopique est possible pour les tumeurs neuroendocrines (TNE) gastriques, duodénoampullaires et rectales. Il réservé aux TNE qui sont résécables en totalité avec des marges saines. Les bons candidats à un tel patients ayant sans critère de malignité, c’est-à-dire risque ganglionnaire nul ou très faible. D’une manière générale, il s’agit bien différenciées, grade 1 (Ki67 ≤2 %), stade (T1N0M0) soit envahissant au maximum la sous-muqueuse, taille ≤10 mm envahissement...
Les petites tumeurs neuroendocrines (TNE) du rectum sont de bons candidats à la résection endoscopique, condition que celle-ci soit carcinologiquement complète (R0) et le risque d'évolution métastatique faible. Cependant les résections endoscopiques doivent encore faire preuve leur efficacité. Nous avons donc mené une étude nationale multicentrique pour évaluer résultats prise en charge endoscopique des TNE rectales initialement non métastatiques ≤2 cm.